144 related articles for article (PubMed ID: 37192729)
1. Tissue factor overexpression in triple-negative breast cancer promotes immune evasion by impeding T-cell infiltration and effector function.
Ren Z; Xue Y; Liu L; Zhang X; Pei J; Zhang Y; Wang Y; Yu K
Cancer Lett; 2023 Jul; 565():216221. PubMed ID: 37192729
[TBL] [Abstract][Full Text] [Related]
2. Tissue factor overexpression promotes resistance to KRAS-G12C inhibition in non-small cell lung cancer.
Zhang Y; Liu L; Pei J; Ren Z; Deng Y; Yu K
Oncogene; 2024 Feb; 43(9):668-681. PubMed ID: 38191673
[TBL] [Abstract][Full Text] [Related]
3. Targeting Tissue Factor for Immunotherapy of Triple-Negative Breast Cancer Using a Second-Generation ICON.
Hu Z; Shen R; Campbell A; McMichael E; Yu L; Ramaswamy B; London CA; Xu T; Carson WE
Cancer Immunol Res; 2018 Jun; 6(6):671-684. PubMed ID: 29622581
[TBL] [Abstract][Full Text] [Related]
4. Regulatory T cells are associated with the tumor immune microenvironment and immunotherapy response in triple-negative breast cancer.
Huang P; Zhou X; Zheng M; Yu Y; Jin G; Zhang S
Front Immunol; 2023; 14():1263537. PubMed ID: 37767092
[TBL] [Abstract][Full Text] [Related]
5. Adaptive antitumor immune response stimulated by bio-nanoparticle based vaccine and checkpoint blockade.
Bai X; Zhou Y; Yokota Y; Matsumoto Y; Zhai B; Maarouf N; Hayashi H; Carlson R; Zhang S; Sousa A; Sun B; Ghanbari H; Dong X; Wands JR
J Exp Clin Cancer Res; 2022 Apr; 41(1):132. PubMed ID: 35392977
[TBL] [Abstract][Full Text] [Related]
6. FGFR blockade boosts T cell infiltration into triple-negative breast cancer by regulating cancer-associated fibroblasts.
Wu Y; Yi Z; Li J; Wei Y; Feng R; Liu J; Huang J; Chen Y; Wang X; Sun J; Yin X; Li Y; Wan J; Zhang L; Huang J; Du H; Wang X; Li Q; Ren G; Li H
Theranostics; 2022; 12(10):4564-4580. PubMed ID: 35832090
[No Abstract] [Full Text] [Related]
7. Therapeutic efficacy and mechanism of CD73-TGFβ dual-blockade in a mouse model of triple-negative breast cancer.
Xing Y; Ren ZQ; Jin R; Liu L; Pei JP; Yu K
Acta Pharmacol Sin; 2022 Sep; 43(9):2410-2418. PubMed ID: 35082394
[TBL] [Abstract][Full Text] [Related]
8. Targeting CD73 with flavonoids inhibits cancer stem cells and increases lymphocyte infiltration in a triple-negative breast cancer mouse model.
Mediratta K; El-Sahli S; Marotel M; Awan MZ; Kirkby M; Salkini A; Kurdieh R; Abdisalam S; Shrestha A; Di Censo C; Sulaiman A; McGarry S; Lavoie JR; Liu Z; Lee SH; Li X; Sciumè G; D'Costa VM; Ardolino M; Wang L
Front Immunol; 2024; 15():1366197. PubMed ID: 38601156
[TBL] [Abstract][Full Text] [Related]
9. Tissue factor as a new target for CAR-NK cell immunotherapy of triple-negative breast cancer.
Hu Z
Sci Rep; 2020 Feb; 10(1):2815. PubMed ID: 32071339
[TBL] [Abstract][Full Text] [Related]
10. Combination of verteporfin-photodynamic therapy with 5-aza-2'-deoxycytidine enhances the anti-tumour immune response in triple negative breast cancer.
Banerjee SM; Acedo P; El Sheikh S; Harati R; Meecham A; Williams NR; Gerard G; Keshtgar MRS; MacRobert AJ; Hamoudi R
Front Immunol; 2023; 14():1188087. PubMed ID: 38022682
[TBL] [Abstract][Full Text] [Related]
11. Syntenin1/MDA-9 (SDCBP) induces immune evasion in triple-negative breast cancer by upregulating PD-L1.
Liu J; Yang Y; Wang H; Wang B; Zhao K; Jiang W; Bai W; Liu J; Yin J
Breast Cancer Res Treat; 2018 Sep; 171(2):345-357. PubMed ID: 29845474
[TBL] [Abstract][Full Text] [Related]
12. Effect of cabazitaxel on macrophages improves CD47-targeted immunotherapy for triple-negative breast cancer.
Cao X; Li B; Chen J; Dang J; Chen S; Gunes EG; Xu B; Tian L; Muend S; Raoof M; Querfeld C; Yu J; Rosen ST; Wang Y; Feng M
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33753567
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of basal-like breast cancer growth by FTY720 in combination with epidermal growth factor receptor kinase blockade.
Martin JL; Julovi SM; Lin MZ; de Silva HC; Boyle FM; Baxter RC
Breast Cancer Res; 2017 Aug; 19(1):90. PubMed ID: 28778177
[TBL] [Abstract][Full Text] [Related]
14. ImmunoPET of tissue factor expression in triple-negative breast cancer with a radiolabeled antibody Fab fragment.
Shi S; Hong H; Orbay H; Graves SA; Yang Y; Ohman JD; Liu B; Nickles RJ; Wong HC; Cai W
Eur J Nucl Med Mol Imaging; 2015 Jul; 42(8):1295-303. PubMed ID: 25801992
[TBL] [Abstract][Full Text] [Related]
15. Immunotherapy of triple-negative breast cancer with cathepsin D-targeting antibodies.
Ashraf Y; Mansouri H; Laurent-Matha V; Alcaraz LB; Roger P; Guiu S; Derocq D; Robin G; Michaud HA; Delpech H; Jarlier M; Pugnière M; Robert B; Puel A; Martin L; Landomiel F; Bourquard T; Achour O; Fruitier-Arnaudin I; Pichard A; Deshayes E; Turtoi A; Poupon A; Simony-Lafontaine J; Boissière-Michot F; Pirot N; Bernex F; Jacot W; du Manoir S; Theillet C; Pouget JP; Navarro-Teulon I; Bonnefoy N; Pèlegrin A; Chardès T; Martineau P; Liaudet-Coopman E
J Immunother Cancer; 2019 Feb; 7(1):29. PubMed ID: 30717773
[TBL] [Abstract][Full Text] [Related]
16. AXL antibody and AXL-ADC mediate antitumor efficacy via targeting AXL in tumor-intrinsic epithelial-mesenchymal transition and tumor-associated M2-like macrophage.
Pei JP; Wang Y; Ma LP; Wang X; Liu L; Zhang Y; Jin R; Ren ZQ; Deng Y; Shen JK; Meng T; Yu K
Acta Pharmacol Sin; 2023 Jun; 44(6):1290-1303. PubMed ID: 36650292
[TBL] [Abstract][Full Text] [Related]
17. MYC suppresses STING-dependent innate immunity by transcriptionally upregulating DNMT1 in triple-negative breast cancer.
Wu SY; Xiao Y; Wei JL; Xu XE; Jin X; Hu X; Li DQ; Jiang YZ; Shao ZM
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34321275
[TBL] [Abstract][Full Text] [Related]
18. PRKCQ promotes oncogenic growth and anoikis resistance of a subset of triple-negative breast cancer cells.
Byerly J; Halstead-Nussloch G; Ito K; Katsyv I; Irie HY
Breast Cancer Res; 2016 Sep; 18(1):95. PubMed ID: 27663795
[TBL] [Abstract][Full Text] [Related]
19. Granzyme B-based cytolytic fusion protein targeting EpCAM specifically kills triple negative breast cancer cells in vitro and inhibits tumor growth in a subcutaneous mouse tumor model.
Amoury M; Kolberg K; Pham AT; Hristodorov D; Mladenov R; Di Fiore S; Helfrich W; Kiessling F; Fischer R; Pardo A; Thepen T; Hussain AF; Nachreiner T; Barth S
Cancer Lett; 2016 Mar; 372(2):201-9. PubMed ID: 26806809
[TBL] [Abstract][Full Text] [Related]
20. MUC1-C integrates activation of the IFN-γ pathway with suppression of the tumor immune microenvironment in triple-negative breast cancer.
Yamashita N; Long M; Fushimi A; Yamamoto M; Hata T; Hagiwara M; Bhattacharya A; Hu Q; Wong KK; Liu S; Kufe D
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33495298
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
